CAMBRIDGE, Mass., May 14, 2015 (BUSINESS WIRE) — InVivo Therapeutics Holdings Corp. (NVIV) today announced a six-month post-implant update for the first study patient and a three-month post-implant update for the second study patient in the company’s ongoing pilot trial of